Table 2.
Total (252 patients) | Nosocomial infection (97 patients) | No nosocomial infection (155 patients) | p value | |
---|---|---|---|---|
Age in years, mean (SD) | 85 ± 6 | 85 ± 5.4 | 84 ± 6.2 | 0.295 |
Female gender, n (%) | 181(67.9) | 68 (70.1) | 113(72.9) | 0.631 |
CD4 T-cell count* | 682 (555-967) | 685 (534-951) | 680 (561-990) | 0.83 |
CD8 T-cell count* | 312 (206-447) | 348(207-557) | 272 (206-412) | 0.06 |
CD4/CD8 ratio | 2.5 (1.4-3.5) | 2.1 (1.3-3.2) | 2.6 (1. 6-3.8) | 0.027 |
NK cell count* | 176 (112-258) | 186 (112-262) | 160 (110-255) | 0.38 |
B cell count* | 126 (78-175) | 133 (78-175) | 117 (78-184) | 0.83 |
CD4 T cells | ||||
Naive (CD45RA+CD62L+)%** | 17.7 (13.2-22.9) | 16.3 (8.8-24.2) | 18.7 (12.5-28.1) | 0.03 |
Absolute value/μL | 242 (148-388) | 214 (125-385) | 260 (155-390) | 0.09 |
Memory | ||||
Peripheral (CD45RA-CD62L-)%** | 6.5 (4.5-9.3) | 6.6 (4.5-9.5) | 6.5 (4.5-9.3) | 0.49 |
Absolute value/μL | 99 (56-152) | 109 (64-156) | 96 (53-150) | 0.29 |
Central (CD45RA-CD62L+)%** | 18.2 (10.5-26.9 | 16.9 (12.9-23.1) | 18.3 (13.5-22.9) | 0.35 |
Absolute value/μL | 256 (175-351) | 249 (174-358) | 262 (172-350) | 0.91 |
CD45RA+CD62L-%** | 0.6 (0.3-1.4) | 0.6 (0.2-1.4) | 0.6 (0.3-1.3) | 0.97 |
Absolute value/μL | 9 (3-22) | 9 (3-24) | 9 (4-20) | 0.93 |
CD8 T cells | ||||
Naive (CD45RA+CD62L+)% | 5 (3.3-7.4) | 4.3 (2.9-6.9) | 5.2 (3.8-8) | 0.006 |
Absolute value/μL | 73 (44-115) | 67 (39-107) | 80 (46-125) | 0.03 |
Memory | ||||
Peripheral (CD45RA-CD62L-)% | 2.8 (1.5-4.9) | 3.1 (1.6-6.2) | 2.6 (1.4-4.0) | 0.02 |
Absolute value/μL | 44 (20-76) | 49 (23-92) | 37 (17-71) | 0.01 |
Central (CD45RA-CD62L+)% | 2.7 (1.7-3.9) | 3 (1.8-3.9) | 2.6 (1.6-4.1) | 0.32 |
Absolute value/μL | 38 (23-59) | 41 (26-61) | 36 (23-57) | 0.22 |
Terminal Effector | ||||
CD45RA+CD62L-% | 7.9 (4-12.9) | 8.5(3.8-16.2) | 7.2 (4.1-11.9) | 0.15 |
Absolute value/μL | 109 (54-191) | 135(60-233) | 101(54-169) | 0.11 |
CD28-% | 56.7 (42.5-73) | 51.8 (40-66) | 53.6 (40-68) | 0.02 |
Absolute value/μL | 153 (88-272) | 196 (91-357) | 139 (88-248) | 0.01 |
IRP criteria***(n = 240) | ||||
CD4/CD8 < 1 (n = 245) | 20 (8.2) | 10 (10.5) | 10 (6.7) | 0.34 |
CD8 T-cells > 600 (n = 245) | 32 (13.1) | 17 (17.9) | 15 (10.0) | 0.07 |
CD28-CD8+ T-cells > 300 (n = 238) | 64 (26.9) | 31 (33.3) | 33 (22.8) | 0.07 |
Positive CMV serology (n = 246) | 193 (78.5) | 76 (79) | 117 (78) | 0.87 |
Positive IRP (n = 240, 95/145) | 60 (25) | 29 (30.5) | 31 (21.4) | 0.11 |
The data are medians and 25-75 percentiles, unless otherwise stated.
*Number of cells per microliter: the main lymphocyte subsets and terminal effector CD28- CD8 cells were counted directly as absolute numbers per microliter of blood (single-platform flow cytometry).
**% of total lymphocytes. Naive and memory subsets were assessed as percentages of total blood lymphocytes, and their absolute counts were computed based on the absolute counts of CD4 and CD8 T cells
***The Immune Risk Phenotype (IRP) was defined as positive CMV serology plus at least one of the three following criteria: CD4/CD8 ratio < 1, CD8T-cells > 600 cells/μL, and CD28 negative T-cells > 300 cells/μL.